Phase II Trial of Intravenous Administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

Reovirus, a replication competent RNA virus, has preclinical activity against melanoma lines and xenografts. We conducted a phase II trial of reovirus in metastatic melanoma patients. Patients received 3 × 10(10) TCID50 on days 1–5 of each 28 day cycle, administered intravenously. Twenty-one eligibl...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Galanis, Evanthia, Markovic, Svetomir N, Suman, Vera J, Nuovo, Gerard J, Vile, Richard G, Kottke, Timothy J, Nevala, Wendy K, Thompson, Michael A, Lewis, Jean E, Rumilla, Kandelaria M, Roulstone, Victoria, Harrington, Kevin, Linette, Gerald P, Maples, William J, Coffey, Matt, Zwiebel, James, Kendra, Kari
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2012
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3464629/
https://ncbi.nlm.nih.gov/pubmed/22871663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2012.146
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים